Tretinoin vs. new-generation retinoids: efficacy without irritation

March 2, 2026 by
Tretinoin vs. new-generation retinoids: efficacy without irritation
LASART S.R.L.

The problem of classic retinoids

Tretinoin has been considered the dermatological "gold standard" for the treatment of acne, photoaging, and hyperpigmentation for decades. However, clinical reality tells a different story: nearly 1 in 4 patients discontinues treatment due to side effects. Burning, erythema, scaling, and photosensitivity-these effects are not uncommon and are common in the first few weeks of use.

This guide analyzes the differences between tretinoin, retinol, and the new generation of retinoids particularly oleyl adapalenate with scientific data, explaining why seeking an alternative to tretinoin is not a matter of convenience, but a smart choice based on molecular biology.


How tretinoin works: mechanism and limitations

Tretinoin (all-trans-retinoic acid) is a first-generation retinoid that binds nonselectively to all three subtypes of nuclear retinoic acid receptors: RAR-α, RAR-β, and RAR-γ. This lack of selectivity explains both its potency and its tolerability issues.

When tretinoin binds to RAR-α and RAR-β receptors in basal keratinocytes and dermal cells, it triggers an inflammatory response that manifests as classic “retinoid irritation”: redness and scaling appear within the first 7–10 days, with peak symptoms occurring within the first 2–4 weeks.

Documented side effects of topical tretinoin (FDA drug labeling):

  • Itching and skin pain
  • Erythema (persistent redness)
  • Flaking and peeling
  • Intense skin dryness
  • Photosensitivity: the skin becomes vulnerable to UV rays
  • Instability to UV light: Tretinoin loses 80% of its activity in just 2 hours of sun exposure

A critical finding regarding photostability: spectrophotometric analyses show that tretinoin rapidly degrades in sunlight, effectively rendering it unusable in daytime formulations. This requires use exclusively in the evening, with all the resulting limitations on therapeutic adherence.


The phenomenon of "retinization"

The initial adaptation period—known as "retinization" or "retinoid uglies"—typically lasts 2 to 6 weeks. During this phase, many patients experience a paradoxical worsening of their skin before seeing any benefits. It is precisely during this time that the vast majority of treatment discontinuations occur.

Side effects


According to scientific literature, with 1% retinol, a full 47.3% of patients reported side effects at 12 weeks; with 0.025% tretinoin, the percentage drops to 12.6% but remains significant. The discontinuation rate due to irritation with traditional retinoids ranges between 15% and 25%.

Source: McDaniel et al., Journal of Cosmetic Dermatology, 2017.


Retinol: Popular, but not without problems

Retinol is the most widely used OTC retinoid in the world. Technically, it's a prodrug: the skin must convert it in two successive steps (retinaldehyde → retinoic acid) before it becomes biologically active. This mechanism has two important consequences.

Retinol conversion with gene activation and adverse effects

Pros: Gradual conversion reduces the intensity of acute irritation compared to direct tretinoin.

Cons: Conversion is partial and varies from individual to individual. Retinol is photosensitive and degrades rapidly if left unprotected. Most importantly, like tretinoin, it is not selective for RAR receptors—it acts on α, β, and γ—retaining its irritant potential.

The most worrying finding remains the incidence of side effects: nearly half of patients using 1% retinol report problems within 12 weeks. This makes retinol the worst in terms of tolerability among the retinoids compared in the literature.


The next-generation alternative: oleyl adapalenate

Oleyl adapalenate is a third-generation synthetic retinoid derived from naphthoic acid, obtained by esterifying adapalene with oleic alcohol. This chemical modification is not cosmetic: it radically changes the biological activity and tolerability profile.

Enzymatic release of active adapalene

Enzymatic release of adapalene: the esterified form is cleaved by skin enzymes, releasing the pure active ingredient for a targeted and controlled action.


Receptor selectivity: the key to advantage

Unlike tretinoin and retinol, oleyl adapalenate selectively binds to RAR-γ receptors present in epidermal keratinocytes. RAR-α and RAR-β receptors—responsible for the inflammatory cascade that causes irritation—are essentially spared. The practical result is documented in the literature: 70% less erythema, scaling, and dryness compared to 0.5% retinol.

Source: Verschoore et al., British Journal of Dermatology, 1999.


Direct anti-inflammatory action

Adapalene possesses a property that neither tretinoin nor retinol possess: a direct anti-inflammatory effect. It inhibits lipoxygenase and arachidonic acid, reducing the production of pro-inflammatory leukotrienes and prostaglandins. This mechanism is particularly valuable in the treatment of post-inflammatory hyperpigmentation, where residual inflammation perpetuates melanin production.

Source: Sorg et al., British Journal of Dermatology, 2006.


Photostability: the advantage of daytime use

Oleyl adapalenate retains 90% of its activity after 24 hours of exposure to UV light. This allows, with adequate sun protection, even morning use, significantly increasing routine flexibility and therapeutic adherence.

Source: Thielitz et al., Photodermatology, Photoimmunology & Photomedicine, 2008.


Comparable efficacy with superior tolerability

A common objection to the adoption of new-generation retinoids is that they are "less effective." Data contradict this belief: in a randomized, multicenter study of 147 acne patients, 0.1% adapalenate gel achieved a 46% reduction in comedones versus 43% for 0.025% tretinoin, with a 44% vs. 40% reduction in inflammatory lesions, respectively. The efficacy was essentially equivalent, but the tolerability was significantly better.

Efficacy of adapalenate compared to tretinoin


Source: Shalita et al., Journal of the American Academy of Dermatology, 1996.


Comparison table: tretinoin vs. retinol vs. oleyl adapalenate

Scientific comparison based on clinical studies published in peer-reviewed journals.

Parameter 

Tretinoin 
(0.025%)

Retinol 
(1%)

Oleyl Adapalenate

Target receptors

RAR-α, β, γ

RAR-α, β, γ

RAR-γ selettivo

Side effects (%)

12,6%

47,3%

< 5%

Reducing irritation vs. retinol

Moderate

-

-70%

Fotostabilità UV

- 80% in 2h

Instabile

−10% in 24h

Direct anti-inflammatory action

No

No

 Sì

Daytime use possible

Not recommended

Not recommended

Sì (con SPF)

Discontinuation of treatment due to irritation

15-25%

Very high

< 5%*

Sensitive skin safety

Poor

Average

Excellent

Availability in Italy

Prescription only

OTC

OTC (Lumicor)

Sources: Shalita et al. (JAAD 1996), Verschoore et al. (BJD 1999), McDaniel et al. (JCD 2017), Thielitz et al. (PPAUM 2008).


Who should choose an alternative to tretinoin?

Tretinoin remains an effective drug for some specific indications, but there are patient profiles for which new-generation retinoids represent a clearly superior choice:

  • Sensitive or reactive skin: irritation from tretinoin can worsen conditions such as rosacea, atopic dermatitis, or post-procedure skin.
  • Post-laser hyperpigmentation treatment: The anti-inflammatory action of oleyl adapalenate prevents the risk of hyperpigmentation from trauma while promoting cell renewal. Read: Post-laser hyperpigmentation.
  • Phototypes dark (III–VI according to Fitzpatrick): increased risk of post-inflammatory hyperpigmentation from retinoid irritation.
  • Use during the day: the photostability of adapalenate allows for flexibility of use not possible with tretinoin.
  • Patients who have already stopped taking tretinoin due to intolerance: switching to a RAR-γ-selective retinoid dramatically reduces the likelihood of experiencing the same problems again.
  • OTC cosmetic use without a prescription: Oleyl adapalenate is available in cosmetic formulations without a prescription.


Oleyl adapalenate in practice: Melicor's anti-hyperpigmentation formula

Melicor has integrated oleyl adapalenate into Lumicor, an anti-hyperpigmentation cream that combines three complementary mechanisms of action in a single scientifically designed formulation:

  • Oleyl adapalenate: accelerates the exfoliation of melanin deposited in the superficial layers, normalizes epidermal turnover, exerts a direct anti-inflammatory action.
  • Cetyl tranexamate mesylate (highly bioavailable tranexamic acid): blocks pro-melanogenic signals at the level of keratinocytes, inhibits the transmission of melanogenic information from melanocytes.
  • Tetraidrocurcumina (bioactive form of turmeric): directly inhibits tyrosinase, the key enzyme in melanin synthesis.

Lumicor crema anti-iperpigmentazione con oleyl adapalenate e acido tranexamico Melicor

This "triple-action" synergy acts on three distinct levels of the pigmentation cascade: blocking production, interrupting transmission, and accelerating elimination. The combined effect is documented as superior to any single lightening agent.

LUMICOR

Expected clinical results:

Weeks

Expected result

1–2

Skin adaptation, possible mild transient erythema

3–4

Beginning of improvement in tone, more uniform texture

4–8

Progressive reduction of blemishes, visible lightening

8–12

Maximum result: significant reduction of hyperpigmentation

Discover Lumicor - anti-hyperpigmentation cream with tranexamic acid on melicor.it


Frequently Asked Questions (FAQ)


Related insights on melicor.it


Share this post
Tags